Trials / Terminated
TerminatedNCT00632424
Phase 1 Trial of Oral Ixabepilone
A Phase 1 Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- R-Pharm · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants with advanced cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone (oral formulation) | Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-03-10
- Last updated
- 2016-03-10
- Results posted
- 2010-12-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00632424. Inclusion in this directory is not an endorsement.